Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 16 entries
Sorted by: Best Match Show Resources per page
Predictive Value of Soluble PD-1, PD-L1, VEGFA, CD40 Ligand and CD44 for Nivolumab Therapy in Advanced Non-Small Cell Lung Cancer: A Case-Control Study.

Cancers

Tiako Meyo M, Jouinot A, Giroux-Leprieur E, Fabre E, Wislez M, Alifano M, Leroy K, Boudou-Rouquette P, Tlemsani C, Khoudour N, Arrondeau J, Thomas-Schoemann A, Blons H, Mansuet-Lupo A, Damotte D, Vidal M, Goldwasser F, Alexandre J, Blanchet B.
PMID: 32085544
Cancers (Basel). 2020 Feb 18;12(2). doi: 10.3390/cancers12020473.

A large interindividual variability has been observed in anti Programmed cell Death 1 (anti-PD1) therapies efficacy. The aim of this study is to assess the correlation of soluble PD-1 (sPD-1), soluble Programmed cell Death Ligand 1 (sPD-L1), Vascular Endothelial...

Cite
Tiako Meyo M, Jouinot A, Giroux-Leprieur E, et al. Predictive Value of Soluble PD-1, PD-L1, VEGFA, CD40 Ligand and CD44 for Nivolumab Therapy in Advanced Non-Small Cell Lung Cancer: A Case-Control Study. Cancers (Basel). 2020;12(2)doi: 10.3390/cancers12020473.
Tiako Meyo, M., Jouinot, A., Giroux-Leprieur, E., Fabre, E., Wislez, M., Alifano, M., Leroy, K., Boudou-Rouquette, P., Tlemsani, C., Khoudour, N., Arrondeau, J., Thomas-Schoemann, A., Blons, H., Mansuet-Lupo, A., Damotte, D., Vidal, M., Goldwasser, F., Alexandre, J., & Blanchet, B. (2020). Predictive Value of Soluble PD-1, PD-L1, VEGFA, CD40 Ligand and CD44 for Nivolumab Therapy in Advanced Non-Small Cell Lung Cancer: A Case-Control Study. Cancers, 12(2), . https://doi.org/10.3390/cancers12020473
Tiako Meyo, Manuela, et al. "Predictive Value of Soluble PD-1, PD-L1, VEGFA, CD40 Ligand and CD44 for Nivolumab Therapy in Advanced Non-Small Cell Lung Cancer: A Case-Control Study." Cancers vol. 12,2 (2020). doi: https://doi.org/10.3390/cancers12020473
Tiako Meyo M, Jouinot A, Giroux-Leprieur E, Fabre E, Wislez M, Alifano M, Leroy K, Boudou-Rouquette P, Tlemsani C, Khoudour N, Arrondeau J, Thomas-Schoemann A, Blons H, Mansuet-Lupo A, Damotte D, Vidal M, Goldwasser F, Alexandre J, Blanchet B. Predictive Value of Soluble PD-1, PD-L1, VEGFA, CD40 Ligand and CD44 for Nivolumab Therapy in Advanced Non-Small Cell Lung Cancer: A Case-Control Study. Cancers (Basel). 2020 Feb 18;12(2). doi: 10.3390/cancers12020473. PMID: 32085544; PMCID: PMC7072584.
Copy Download .nbib Format: NLM
Treatment of 120 adult osteosarcoma patients with metachronous and synchronous metastases: A retrospective series of the French Sarcoma Group.

International journal of cancer

Lavit E, Aldea M, Piperno-Neumann S, Firmin N, Italiano A, Isambert N, Kurtz JE, Delcambre C, Lebrun V, Soibinet-Oudot P, Chevreau C, Bompas E, Le Maignan C, Boudou-Rouquette P, Le Cesne A, Mancini J, Blay JY, Duffaud F.
PMID: 34562271
Int J Cancer. 2021 Sep 25; doi: 10.1002/ijc.33823. Epub 2021 Sep 25.

Treatment options for metastatic osteosarcomas are scarce. Following failure of standard first line therapy, patients who relapse present a challenging treatment dilemma, and have a poor prognosis. Surgical removal of all metastases is essential. A retrospective analysis of patients...

Cite
Lavit E, Aldea M, Piperno-Neumann S, et al. Treatment of 120 adult osteosarcoma patients with metachronous and synchronous metastases: A retrospective series of the French Sarcoma Group. Int J Cancer. 2021;doi: 10.1002/ijc.33823.
Lavit, E., Aldea, M., Piperno-Neumann, S., Firmin, N., Italiano, A., Isambert, N., Kurtz, J. E., Delcambre, C., Lebrun, V., Soibinet-Oudot, P., Chevreau, C., Bompas, E., Le Maignan, C., Boudou-Rouquette, P., Le Cesne, A., Mancini, J., Blay, J. Y., & Duffaud, F. (2021). Treatment of 120 adult osteosarcoma patients with metachronous and synchronous metastases: A retrospective series of the French Sarcoma Group. International journal of cancer, . https://doi.org/10.1002/ijc.33823
Lavit, Elise, et al. "Treatment of 120 adult osteosarcoma patients with metachronous and synchronous metastases: A retrospective series of the French Sarcoma Group." International journal of cancer vol. (2021). doi: https://doi.org/10.1002/ijc.33823
Lavit E, Aldea M, Piperno-Neumann S, Firmin N, Italiano A, Isambert N, Kurtz JE, Delcambre C, Lebrun V, Soibinet-Oudot P, Chevreau C, Bompas E, Le Maignan C, Boudou-Rouquette P, Le Cesne A, Mancini J, Blay JY, Duffaud F. Treatment of 120 adult osteosarcoma patients with metachronous and synchronous metastases: A retrospective series of the French Sarcoma Group. Int J Cancer. 2021 Sep 25; doi: 10.1002/ijc.33823. Epub 2021 Sep 25. PMID: 34562271.
Copy Download .nbib Format: NLM
Reply to Bone morphogenetic proteins and zoledronic acid.

Annals of oncology : official journal of the European Society for Medical Oncology

Bertagna X, Boudou-Rouquette P, Alexandre J, Soubrane O, Goldwasser F.
PMID: 32560025
Ann Oncol. 2009 Dec;20(12):2019. doi: 10.1093/annonc/mdp503. Epub 2019 Dec 04.

No abstract available.

Cite
Bertagna X, Boudou-Rouquette P, Alexandre J, et al. Reply to Bone morphogenetic proteins and zoledronic acid. Ann Oncol. 2019;20(12):2019doi: 10.1093/annonc/mdp503.
Bertagna, X., Boudou-Rouquette, P., Alexandre, J., Soubrane, O., & Goldwasser, F. (2009). Reply to Bone morphogenetic proteins and zoledronic acid. Annals of oncology : official journal of the European Society for Medical Oncology, 20(12), 2019. https://doi.org/10.1093/annonc/mdp503
Bertagna, X, et al. "Reply to Bone morphogenetic proteins and zoledronic acid." Annals of oncology : official journal of the European Society for Medical Oncology vol. 20,12 (2009): 2019. doi: https://doi.org/10.1093/annonc/mdp503
Bertagna X, Boudou-Rouquette P, Alexandre J, Soubrane O, Goldwasser F. Reply to Bone morphogenetic proteins and zoledronic acid. Ann Oncol. 2009 Dec;20(12):2019. doi: 10.1093/annonc/mdp503. Epub 2019 Dec 04. PMID: 32560025.
Copy Download .nbib Format: NLM
Pituitary Lesion of Unknown Origin: Think Epithelioid Angiosarcoma.

Journal of the Endocrine Society

Bricaire L, Villa C, Brière M, Edjlali M, Larousserie F, d'Ussel M, Bertherat J, Boudou-Rouquette P, Groussin L.
PMID: 29264447
J Endocr Soc. 2017 Jan 12;1(1):72-74. doi: 10.1210/js.2016-1010. eCollection 2017 Jan 01.

No abstract available.

Cite
Bricaire L, Villa C, Brière M, et al. Pituitary Lesion of Unknown Origin: Think Epithelioid Angiosarcoma. J Endocr Soc. 2017;1(1):72-74doi: 10.1210/js.2016-1010.
Bricaire, L., Villa, C., Brière, M., Edjlali, M., Larousserie, F., d'Ussel, M., Bertherat, J., Boudou-Rouquette, P., & Groussin, L. (2017). Pituitary Lesion of Unknown Origin: Think Epithelioid Angiosarcoma. Journal of the Endocrine Society, 1(1), 72-74. https://doi.org/10.1210/js.2016-1010
Bricaire, Léopoldine, et al. "Pituitary Lesion of Unknown Origin: Think Epithelioid Angiosarcoma." Journal of the Endocrine Society vol. 1,1 (2017): 72-74. doi: https://doi.org/10.1210/js.2016-1010
Bricaire L, Villa C, Brière M, Edjlali M, Larousserie F, d'Ussel M, Bertherat J, Boudou-Rouquette P, Groussin L. Pituitary Lesion of Unknown Origin: Think Epithelioid Angiosarcoma. J Endocr Soc. 2017 Jan 12;1(1):72-74. doi: 10.1210/js.2016-1010. eCollection 2017 Jan 01. PMID: 29264447; PMCID: PMC5677211.
Copy Download .nbib Format: NLM
Rare bone sarcomas: A retrospective analysis of 145 adult patients from the French Sarcoma Group.

International journal of cancer

Boudou-Rouquette P, Martin E, Kempf E, Penel N, Toulmonde M, Bompas E, Duffaud F, Firmin N, Bertucci F, Kurtz JE, Chaigneau L, Isambert N, Saada-Bouzid E, Dubray-Longeras P, Larousserie F, Anract P, Chevreau C, Blay JY, Piperno-Neumann S.
PMID: 34611903
Int J Cancer. 2021 Oct 06; doi: 10.1002/ijc.33837. Epub 2021 Oct 06.

The benefit of chemotherapy (CT) in rare bone sarcomas is not documented in prospective studies. Our retrospective study from the French sarcoma network for bone tumors ResOs was performed in adult patients (pts) from 1976 to 2014, with histologically...

Cite
Boudou-Rouquette P, Martin E, Kempf E, et al. Rare bone sarcomas: A retrospective analysis of 145 adult patients from the French Sarcoma Group. Int J Cancer. 2021;doi: 10.1002/ijc.33837.
Boudou-Rouquette, P., Martin, E., Kempf, E., Penel, N., Toulmonde, M., Bompas, E., Duffaud, F., Firmin, N., Bertucci, F., Kurtz, J. E., Chaigneau, L., Isambert, N., Saada-Bouzid, E., Dubray-Longeras, P., Larousserie, F., Anract, P., Chevreau, C., Blay, J. Y., Piperno-Neumann, S. (2021). Rare bone sarcomas: A retrospective analysis of 145 adult patients from the French Sarcoma Group. International journal of cancer, . https://doi.org/10.1002/ijc.33837
Boudou-Rouquette, Pascaline, et al. "Rare bone sarcomas: A retrospective analysis of 145 adult patients from the French Sarcoma Group." International journal of cancer vol. (2021). doi: https://doi.org/10.1002/ijc.33837
Boudou-Rouquette P, Martin E, Kempf E, Penel N, Toulmonde M, Bompas E, Duffaud F, Firmin N, Bertucci F, Kurtz JE, Chaigneau L, Isambert N, Saada-Bouzid E, Dubray-Longeras P, Larousserie F, Anract P, Chevreau C, Blay JY, Piperno-Neumann S. Rare bone sarcomas: A retrospective analysis of 145 adult patients from the French Sarcoma Group. Int J Cancer. 2021 Oct 06; doi: 10.1002/ijc.33837. Epub 2021 Oct 06. PMID: 34611903.
Copy Download .nbib Format: NLM
Rare bone sarcomas: A retrospective analysis of 145 adult patients from the French Sarcoma Group.

International journal of cancer

Boudou-Rouquette P, Martin E, Kempf E, Penel N, Toulmonde M, Bompas E, Duffaud F, Firmin N, Bertucci F, Kurtz JE, Chaigneau L, Isambert N, Saada-Bouzid E, Dubray-Longeras P, Larousserie F, Anract P, Chevreau C, Blay JY, Piperno-Neumann S.
PMID: 34611903
Int J Cancer. 2022 Mar 01;150(5):825-836. doi: 10.1002/ijc.33837. Epub 2021 Nov 05.

The benefit of chemotherapy (CT) in rare bone sarcomas is not documented in prospective studies. Our retrospective study from the French sarcoma network for bone tumors ResOs was performed in adult patients (pts) from 1976 to 2014, with histologically...

Cite
Boudou-Rouquette P, Martin E, Kempf E, et al. Rare bone sarcomas: A retrospective analysis of 145 adult patients from the French Sarcoma Group. Int J Cancer. 2021;150(5):825-836doi: 10.1002/ijc.33837.
Boudou-Rouquette, P., Martin, E., Kempf, E., Penel, N., Toulmonde, M., Bompas, E., Duffaud, F., Firmin, N., Bertucci, F., Kurtz, J. E., Chaigneau, L., Isambert, N., Saada-Bouzid, E., Dubray-Longeras, P., Larousserie, F., Anract, P., Chevreau, C., Blay, J. Y., Piperno-Neumann, S. (2022). Rare bone sarcomas: A retrospective analysis of 145 adult patients from the French Sarcoma Group. International journal of cancer, 150(5), 825-836. https://doi.org/10.1002/ijc.33837
Boudou-Rouquette, Pascaline, et al. "Rare bone sarcomas: A retrospective analysis of 145 adult patients from the French Sarcoma Group." International journal of cancer vol. 150,5 (2022): 825-836. doi: https://doi.org/10.1002/ijc.33837
Boudou-Rouquette P, Martin E, Kempf E, Penel N, Toulmonde M, Bompas E, Duffaud F, Firmin N, Bertucci F, Kurtz JE, Chaigneau L, Isambert N, Saada-Bouzid E, Dubray-Longeras P, Larousserie F, Anract P, Chevreau C, Blay JY, Piperno-Neumann S. Rare bone sarcomas: A retrospective analysis of 145 adult patients from the French Sarcoma Group. Int J Cancer. 2022 Mar 01;150(5):825-836. doi: 10.1002/ijc.33837. Epub 2021 Nov 05. PMID: 34611903.
Copy Download .nbib Format: NLM
Development and validation of a host-dependent, PDL1-independent, biomarker to predict 6-month progression-free survival in metastatic non-small cell lung cancer (mNSCLC) patients treated with anti-PD1 immune checkpoint inhibitors (ICI) in the CERTIM Cohort: The ELY study.

EBioMedicine

Boudou-Rouquette P, Arrondeau J, Gervais C, Durand JP, Fabre E, De Percin S, Villeminey CV, Piketty AC, Rassy N, Ulmann G, Damotte D, Mansuet-Lupo A, Giraud F, Alifano M, Wislez M, Alexandre J, Jouinot A, Goldwasser F.
PMID: 34688030
EBioMedicine. 2021 Nov;73:103630. doi: 10.1016/j.ebiom.2021.103630. Epub 2021 Oct 20.

BACKGROUND: Immune checkpoint inhibitors (ICI) are dramatically active in a minority of non-small cell lung cancer (NSCLC) patients. We studied here the relationship between patients's metabolism and outcome under ICI.METHODS: Metastatic NSCLC patients underwent a nutritional assessment prior to...

Cite
Boudou-Rouquette P, Arrondeau J, Gervais C, et al. Development and validation of a host-dependent, PDL1-independent, biomarker to predict 6-month progression-free survival in metastatic non-small cell lung cancer (mNSCLC) patients treated with anti-PD1 immune checkpoint inhibitors (ICI) in the CERTIM Cohort: The ELY study. EBioMedicine. 2021;73:103630doi: 10.1016/j.ebiom.2021.103630.
Boudou-Rouquette, P., Arrondeau, J., Gervais, C., Durand, J. P., Fabre, E., De Percin, S., Villeminey, C. V., Piketty, A. C., Rassy, N., Ulmann, G., Damotte, D., Mansuet-Lupo, A., Giraud, F., Alifano, M., Wislez, M., Alexandre, J., Jouinot, A., & Goldwasser, F. (2021). Development and validation of a host-dependent, PDL1-independent, biomarker to predict 6-month progression-free survival in metastatic non-small cell lung cancer (mNSCLC) patients treated with anti-PD1 immune checkpoint inhibitors (ICI) in the CERTIM Cohort: The ELY study. EBioMedicine, 73103630. https://doi.org/10.1016/j.ebiom.2021.103630
Boudou-Rouquette, Pascaline, et al. "Development and validation of a host-dependent, PDL1-independent, biomarker to predict 6-month progression-free survival in metastatic non-small cell lung cancer (mNSCLC) patients treated with anti-PD1 immune checkpoint inhibitors (ICI) in the CERTIM Cohort: The ELY study." EBioMedicine vol. 73 (2021): 103630. doi: https://doi.org/10.1016/j.ebiom.2021.103630
Boudou-Rouquette P, Arrondeau J, Gervais C, Durand JP, Fabre E, De Percin S, Villeminey CV, Piketty AC, Rassy N, Ulmann G, Damotte D, Mansuet-Lupo A, Giraud F, Alifano M, Wislez M, Alexandre J, Jouinot A, Goldwasser F. Development and validation of a host-dependent, PDL1-independent, biomarker to predict 6-month progression-free survival in metastatic non-small cell lung cancer (mNSCLC) patients treated with anti-PD1 immune checkpoint inhibitors (ICI) in the CERTIM Cohort: The ELY study. EBioMedicine. 2021 Nov;73:103630. doi: 10.1016/j.ebiom.2021.103630. Epub 2021 Oct 20. PMID: 34688030; PMCID: PMC8536532.
Copy Download .nbib Format: NLM
Treatment of 120 adult osteosarcoma patients with metachronous and synchronous metastases: A retrospective series of the French Sarcoma Group.

International journal of cancer

Lavit E, Aldea M, Piperno-Neumann S, Firmin N, Italiano A, Isambert N, Kurtz JE, Delcambre C, Lebrun V, Soibinet-Oudot P, Chevreau C, Bompas E, Le Maignan C, Boudou-Rouquette P, Le Cesne A, Mancini J, Blay JY, Duffaud F.
PMID: 34562271
Int J Cancer. 2022 Feb 15;150(4):645-653. doi: 10.1002/ijc.33823. Epub 2021 Oct 05.

Treatment options for metastatic osteosarcomas are scarce. Following failure of standard first line therapy, patients who relapse present a challenging treatment dilemma, and have a poor prognosis. Surgical removal of all metastases is essential. A retrospective analysis of patients...

Cite
Lavit E, Aldea M, Piperno-Neumann S, et al. Treatment of 120 adult osteosarcoma patients with metachronous and synchronous metastases: A retrospective series of the French Sarcoma Group. Int J Cancer. 2021;150(4):645-653doi: 10.1002/ijc.33823.
Lavit, E., Aldea, M., Piperno-Neumann, S., Firmin, N., Italiano, A., Isambert, N., Kurtz, J. E., Delcambre, C., Lebrun, V., Soibinet-Oudot, P., Chevreau, C., Bompas, E., Le Maignan, C., Boudou-Rouquette, P., Le Cesne, A., Mancini, J., Blay, J. Y., & Duffaud, F. (2022). Treatment of 120 adult osteosarcoma patients with metachronous and synchronous metastases: A retrospective series of the French Sarcoma Group. International journal of cancer, 150(4), 645-653. https://doi.org/10.1002/ijc.33823
Lavit, Elise, et al. "Treatment of 120 adult osteosarcoma patients with metachronous and synchronous metastases: A retrospective series of the French Sarcoma Group." International journal of cancer vol. 150,4 (2022): 645-653. doi: https://doi.org/10.1002/ijc.33823
Lavit E, Aldea M, Piperno-Neumann S, Firmin N, Italiano A, Isambert N, Kurtz JE, Delcambre C, Lebrun V, Soibinet-Oudot P, Chevreau C, Bompas E, Le Maignan C, Boudou-Rouquette P, Le Cesne A, Mancini J, Blay JY, Duffaud F. Treatment of 120 adult osteosarcoma patients with metachronous and synchronous metastases: A retrospective series of the French Sarcoma Group. Int J Cancer. 2022 Feb 15;150(4):645-653. doi: 10.1002/ijc.33823. Epub 2021 Oct 05. PMID: 34562271.
Copy Download .nbib Format: NLM
Is there an Exposure-Response Relationship for Nivolumab in Real-World NSCLC Patients?.

Cancers

Bellesoeur A, Ollier E, Allard M, Hirsch L, Boudou-Rouquette P, Arrondeau J, Thomas-Schoemann A, Tiako M, Khoudour N, Chapron J, Giraud F, Wislez M, Damotte D, Lupo A, Vidal M, Alexandre J, Goldwasser F, Tod M, Blanchet B.
PMID: 31766292
Cancers (Basel). 2019 Nov 13;11(11). doi: 10.3390/cancers11111784.

Pharmacokinetic/pharmacodynamic data from real-world cohort are sparse in non small-cell lung cancer (NSCLC) patients treated with nivolumab. The aim of this prospective observational study was to explore the exposure-response relationship for effectiveness and toxicity of nivolumab in 81 outpatients...

Cite
Bellesoeur A, Ollier E, Allard M, et al. Is there an Exposure-Response Relationship for Nivolumab in Real-World NSCLC Patients?. Cancers (Basel). 2019;11(11)doi: 10.3390/cancers11111784.
Bellesoeur, A., Ollier, E., Allard, M., Hirsch, L., Boudou-Rouquette, P., Arrondeau, J., Thomas-Schoemann, A., Tiako, M., Khoudour, N., Chapron, J., Giraud, F., Wislez, M., Damotte, D., Lupo, A., Vidal, M., Alexandre, J., Goldwasser, F., Tod, M., & Blanchet, B. (2019). Is there an Exposure-Response Relationship for Nivolumab in Real-World NSCLC Patients?. Cancers, 11(11), . https://doi.org/10.3390/cancers11111784
Bellesoeur, Audrey, et al. "Is there an Exposure-Response Relationship for Nivolumab in Real-World NSCLC Patients?." Cancers vol. 11,11 (2019). doi: https://doi.org/10.3390/cancers11111784
Bellesoeur A, Ollier E, Allard M, Hirsch L, Boudou-Rouquette P, Arrondeau J, Thomas-Schoemann A, Tiako M, Khoudour N, Chapron J, Giraud F, Wislez M, Damotte D, Lupo A, Vidal M, Alexandre J, Goldwasser F, Tod M, Blanchet B. Is there an Exposure-Response Relationship for Nivolumab in Real-World NSCLC Patients?. Cancers (Basel). 2019 Nov 13;11(11). doi: 10.3390/cancers11111784. PMID: 31766292; PMCID: PMC6895963.
Copy Download .nbib Format: NLM
Erratum to: Sarcopenic overweight is associated with early acute limiting toxicity of anti-PD1 checkpoint inhibitors in melanoma patients.

Investigational new drugs

Heidelberger V, Goldwasser F, Kramkimel N, Jouinot A, Huillard O, Boudou-Rouquette P, Chanal J, Arrondeau J, Franck N, Alexandre J, Blanchet B, Leroy K, Avril MF, Dupin N, Aractingi S.
PMID: 28597150
Invest New Drugs. 2017 Aug;35(4):537. doi: 10.1007/s10637-017-0475-7.

No abstract available.

Cite
Heidelberger V, Goldwasser F, Kramkimel N, et al. Erratum to: Sarcopenic overweight is associated with early acute limiting toxicity of anti-PD1 checkpoint inhibitors in melanoma patients. Invest New Drugs. 2017;35(4):537doi: 10.1007/s10637-017-0475-7.
Heidelberger, V., Goldwasser, F., Kramkimel, N., Jouinot, A., Huillard, O., Boudou-Rouquette, P., Chanal, J., Arrondeau, J., Franck, N., Alexandre, J., Blanchet, B., Leroy, K., Avril, M. F., Dupin, N., & Aractingi, S. (2017). Erratum to: Sarcopenic overweight is associated with early acute limiting toxicity of anti-PD1 checkpoint inhibitors in melanoma patients. Investigational new drugs, 35(4), 537. https://doi.org/10.1007/s10637-017-0475-7
Heidelberger, Valentine, et al. "Erratum to: Sarcopenic overweight is associated with early acute limiting toxicity of anti-PD1 checkpoint inhibitors in melanoma patients." Investigational new drugs vol. 35,4 (2017): 537. doi: https://doi.org/10.1007/s10637-017-0475-7
Heidelberger V, Goldwasser F, Kramkimel N, Jouinot A, Huillard O, Boudou-Rouquette P, Chanal J, Arrondeau J, Franck N, Alexandre J, Blanchet B, Leroy K, Avril MF, Dupin N, Aractingi S. Erratum to: Sarcopenic overweight is associated with early acute limiting toxicity of anti-PD1 checkpoint inhibitors in melanoma patients. Invest New Drugs. 2017 Aug;35(4):537. doi: 10.1007/s10637-017-0475-7. PMID: 28597150.
Copy Download .nbib Format: NLM
Prevalence and prognostic impact of cachexia among older patients with cancer: a nationwide cross-sectional survey (NutriAgeCancer).

Journal of cachexia, sarcopenia and muscle

Poisson J, Martinez-Tapia C, Heitz D, Geiss R, Albrand G, Falandry C, Gisselbrecht M, Couderc AL, Boulahssass R, Liuu E, Boudou-Rouquette P, Chah Wakilian A, Gaxatte C, Pamoukdjian F, de Decker L, Antoine V, Cattenoz C, Solem-Laviec H, Guillem O, Medjenah H, Natella PA, Canouï-Poitrine F, Laurent M, Paillaud E.
PMID: 34519440
J Cachexia Sarcopenia Muscle. 2021 Dec;12(6):1477-1488. doi: 10.1002/jcsm.12776. Epub 2021 Sep 14.

BACKGROUND: Nutritional impairment is common in cancer patients and is associated with poor outcomes. Only few studies focused on cachexia. We assessed the prevalence of cachexia in older cancer patients, identified associated risk factors, and evaluated its impact on...

Cite
Poisson J, Martinez-Tapia C, Heitz D, et al. Prevalence and prognostic impact of cachexia among older patients with cancer: a nationwide cross-sectional survey (NutriAgeCancer). J Cachexia Sarcopenia Muscle. 2021;12(6):1477-1488doi: 10.1002/jcsm.12776.
Poisson, J., Martinez-Tapia, C., Heitz, D., Geiss, R., Albrand, G., Falandry, C., Gisselbrecht, M., Couderc, A. L., Boulahssass, R., Liuu, E., Boudou-Rouquette, P., Chah Wakilian, A., Gaxatte, C., Pamoukdjian, F., de Decker, L., Antoine, V., Cattenoz, C., Solem-Laviec, H., Guillem, O., Medjenah, H., Natella, P. A., Canouï-Poitrine, F., Laurent, M., & Paillaud, E. (2021). Prevalence and prognostic impact of cachexia among older patients with cancer: a nationwide cross-sectional survey (NutriAgeCancer). Journal of cachexia, sarcopenia and muscle, 12(6), 1477-1488. https://doi.org/10.1002/jcsm.12776
Poisson, Johanne, et al. "Prevalence and prognostic impact of cachexia among older patients with cancer: a nationwide cross-sectional survey (NutriAgeCancer)." Journal of cachexia, sarcopenia and muscle vol. 12,6 (2021): 1477-1488. doi: https://doi.org/10.1002/jcsm.12776
Poisson J, Martinez-Tapia C, Heitz D, Geiss R, Albrand G, Falandry C, Gisselbrecht M, Couderc AL, Boulahssass R, Liuu E, Boudou-Rouquette P, Chah Wakilian A, Gaxatte C, Pamoukdjian F, de Decker L, Antoine V, Cattenoz C, Solem-Laviec H, Guillem O, Medjenah H, Natella PA, Canouï-Poitrine F, Laurent M, Paillaud E. Prevalence and prognostic impact of cachexia among older patients with cancer: a nationwide cross-sectional survey (NutriAgeCancer). J Cachexia Sarcopenia Muscle. 2021 Dec;12(6):1477-1488. doi: 10.1002/jcsm.12776. Epub 2021 Sep 14. PMID: 34519440.
Copy Download .nbib Format: NLM
Predicting Frailty and Geriatric Interventions in Older Cancer Patients: Performance of Two Screening Tools for Seven Frailty Definitions-ELCAPA Cohort.

Cancers

Martinez-Tapia C, Laurent M, Paillaud E, Caillet P, Ferrat E, Lagrange JL, Rwabihama JP, Allain M, Chahwakilian A, Boudou-Rouquette P, Bastuji-Garin S, Audureau E.
PMID: 35008408
Cancers (Basel). 2022 Jan 04;14(1). doi: 10.3390/cancers14010244.

Screening tools have been developed to identify patients warranting a complete geriatric assessment (GA). However, GA lacks standardization and does not capture important aspects of geriatric oncology practice. We measured and compared the diagnostic performance of screening tools G8...

Cite
Martinez-Tapia C, Laurent M, Paillaud E, et al. Predicting Frailty and Geriatric Interventions in Older Cancer Patients: Performance of Two Screening Tools for Seven Frailty Definitions-ELCAPA Cohort. Cancers (Basel). 2022;14(1)doi: 10.3390/cancers14010244.
Martinez-Tapia, C., Laurent, M., Paillaud, E., Caillet, P., Ferrat, E., Lagrange, J. L., Rwabihama, J. P., Allain, M., Chahwakilian, A., Boudou-Rouquette, P., Bastuji-Garin, S., & Audureau, E. (2022). Predicting Frailty and Geriatric Interventions in Older Cancer Patients: Performance of Two Screening Tools for Seven Frailty Definitions-ELCAPA Cohort. Cancers, 14(1), . https://doi.org/10.3390/cancers14010244
Martinez-Tapia, Claudia, et al. "Predicting Frailty and Geriatric Interventions in Older Cancer Patients: Performance of Two Screening Tools for Seven Frailty Definitions-ELCAPA Cohort." Cancers vol. 14,1 (2022). doi: https://doi.org/10.3390/cancers14010244
Martinez-Tapia C, Laurent M, Paillaud E, Caillet P, Ferrat E, Lagrange JL, Rwabihama JP, Allain M, Chahwakilian A, Boudou-Rouquette P, Bastuji-Garin S, Audureau E. Predicting Frailty and Geriatric Interventions in Older Cancer Patients: Performance of Two Screening Tools for Seven Frailty Definitions-ELCAPA Cohort. Cancers (Basel). 2022 Jan 04;14(1). doi: 10.3390/cancers14010244. PMID: 35008408; PMCID: PMC8750824.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 16 entries